{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:11:34Z","timestamp":1784862694397,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ejca.2015.11.015","type":"journal-article","created":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T14:30:52Z","timestamp":1451313052000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["\u2018Tablet burden\u2019 in patients with metastatic breast cancer"],"prefix":"10.1016","volume":"55","author":[{"given":"Marina","family":"Milic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Rihawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Anthoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Twelves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2015.11.015_bib1","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.1998.16.7.2557","article-title":"Oral chemotherapy: rationale and future directions","volume":"16","author":"DeMario","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2015.11.015_bib2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.11.015_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/annonc\/mdm285","article-title":"Effective oral chemotherapy for breast cancer: pillars of strength","volume":"19","author":"Findlay","year":"2008","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2015.11.015_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.critrevonc.2005.03.007","article-title":"Drug-drug interactions in oncology: why are they important and can they be minimized?","volume":"55","author":"Blower","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.ejca.2015.11.015_bib5","first-page":"1052","article-title":"Polypharmacy, aging and cancer","volume":"22","author":"Tam-McDevitt","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ejca.2015.11.015_bib6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/cncr.22867","article-title":"The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer","volume":"110","author":"Chia","year":"2007","journal-title":"Cancer"},{"issue":"9 Suppl 5","key":"10.1016\/j.ejca.2015.11.015_bib7","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2146\/ajhp070035","article-title":"Overview of the changing paradigm in cancer treatment: oral chemotherapy","volume":"64","author":"Aisner","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ejca.2015.11.015_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","article-title":"Patient preference and pharmacokinetics of oral modulated UFT versus IV fluorouracil and leucovorin; a randomised crossover trial in advanced colorectal cancer","volume":"38","author":"Borner","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2015.11.015_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/annonc\/mdj023","article-title":"A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil\/leucovorin regimes in patients with advanced colorectal cancer","volume":"17","author":"Twelves","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.11.015_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pec.2004.10.005","article-title":"Adherence beliefs among breast cancer patients taking tamoxifen","volume":"59","author":"Grunfeld","year":"2005","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.ejca.2015.11.015_bib11","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.clinthera.2012.06.025","article-title":"Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study","volume":"34","author":"Yu","year":"2012","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.ejca.2015.11.015_bib12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jnci\/djk130","article-title":"Potential drug interaction and duplicate prescriptions among cancer patients","volume":"99","author":"Riechelmann","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.ejca.2015.11.015_bib13","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1001\/jama.2008.824","article-title":"Long-term all cause mortality in cancer patients with preexisiting diabetes mellitus","volume":"300","author":"Barone","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2015.11.015_bib14","article-title":"Treating diabetic patients with chemotherapy : single centre experience of toxicity and outcomes","author":"Young","year":"2012","journal-title":"ESMO Congr"},{"key":"10.1016\/j.ejca.2015.11.015_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2009.27.3011","article-title":"Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis","volume":"29","author":"Peairs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.11.015_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.2013-0237","article-title":"Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management","volume":"19","author":"Carter","year":"2014","journal-title":"The Oncologist"},{"key":"10.1016\/j.ejca.2015.11.015_bib17","series-title":"NICE lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of CVD. NICE clinical guideline 181","year":"2014"},{"issue":"9841","key":"10.1016\/j.ejca.2015.11.015_bib18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists'(CTT) collaborators","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2015.11.015_bib19","unstructured":"Rosensan RS. Clinical trials of cholesterol lowering for primary prevention of coronary heart disease, uptodate topic 4558 version 13.0."},{"issue":"4","key":"10.1016\/j.ejca.2015.11.015_bib20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1089\/jpm.2012.0158","article-title":"Statin prescribing patterns in a cohort of cancer patients with poor prognosis","volume":"16","author":"Bayliss","year":"2013","journal-title":"J Palliat Med"},{"issue":"3","key":"10.1016\/j.ejca.2015.11.015_bib21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4143\/crt.2013.45.3.220","article-title":"Evaluation of prescribing medications for terminal cancer patients near death: essential or futile","volume":"45","author":"Lee","year":"2013","journal-title":"Cancer Res Treat"},{"issue":"23","key":"10.1016\/j.ejca.2015.11.015_bib22","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1001\/jama.294.23.2989","article-title":"Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease","volume":"294","author":"Dial","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejca.2015.11.015_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4292\/wjgpt.v2.i3.17","article-title":"Proton-pump inhibitor pneumonia: not a breath of fresh air at all?","volume":"2","author":"Fohl Alexander","year":"2011","journal-title":"World J Gastrointest Pharmacol Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491501093X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491501093X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T11:00:54Z","timestamp":1537095654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491501093X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":23,"alternative-id":["S095980491501093X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.11.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u2018Tablet burden\u2019 in patients with metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}